MoonLake Immunotherapeutics MLTX
$18.97
▲ +5.30% 24H
About
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing next-level therapies for serious inflammatory diseases. The company targets over-expression of interleukins IL-17A and IL-17F, which drive conditions such as psoriasis, hidradenitis suppurativa (HS), psoriatic arthritis (P…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountrySwitzerland
Employees130
TickerMLTX
Statistics
Market Cap$1.37B
Revenue (TTM)—
Net Income-$227.3M
Net Margin—
EPS$-3.53
P/E-5.25
P/S—
P/B4.97
EV/EBITDA-3.90
ROE-77.8%
Dividend Yield—
Price$18.97
Data: Twelve Data · Revenue = mcap / P/S